R-Pharm JSC on Muck Rack

R-Pharm JSC

As seen in: Arthritis Research & Therapy
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with R-Pharm

Contact R-Pharm, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

The impact of comorbidities on the efficacy of IL-6 inhibitor olokizumab compared to adalimumab in a randomized controlled trial - Arthritis Research & Therapy

|
By Experimental Rheumatology, R-Pharm JSC, Eugen Feist, Michael E Luggen, Sergey Yakushin, Daria Bukhanova, Sergey A. Grishin, Josef S Smolen Verified, Evgeny L. Nasonov, Alina N. Egorova, Mikhail Y. Samsonov
| Arthritis Research & Therapy Verified
This post hoc exploratory analysis used the data of patients with moderately to severely active RA who participated in the randomized, double-blind, placebo-controlled and active-controlled phase III study (clinicaltrials.gov NCT02760407, CREDO-2) and received OKZ 64 mg once every 2 weeks (q2w) or 4 weeks (q4w), ADA 40 mg q2w or placebo for 24 weeks of the study treatment period [13].
Open in Who Shared Issue with article?
See all 1 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified